entertainment -WSS

entertainment

author：leisure time 2025-09-30 20:47:23 - browse：34591

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Reanimated hearts work just as well for transplants, study finds

focus

WSS

Eli Lilly’s Mounjaro succeeds in second weight

Medicare to cover more brain scans related to Alzheimer’s drugs

Reanimated hearts work just as well for transplants, study finds

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Biogen nominates mother of director’s child to replace him on board

How clinical AI models' predictive power can degrade over time

focus

entertainment

explore

Medical leaders decry Supreme Court decision on affirmative action

European regulators consider appeal over Amylyx ALS drug

Drug repurposing or repositioning? The language matters

How clinical AI models' predictive power can degrade over time

Affirmative action in medical school literally saved lives

Can medical device makers keep up in the race to treat obesity?

Tori Bowie and the unacceptable rates of Black maternal death

There’s no way to know how good AI health technologies are

Affirmative action in medical school literally saved lives

A fraught question for the kids of Alzheimer’s: Is it coming for us?

hotspot

Patients, doctors are clashing about side effects of hormonal birth control

How clinical AI models' predictive power can degrade over time

Readout LOUD podcast: Merger Mondays, Ozempic panic

Nick Jonas talks about managing diabetes along with his career

The thinking behind the controversial eating disorder chatbot Tessa

FDA approves first new drug developed for postpartum depression

focus

focus

hotspot

focus